Meeting
2013 Genitourinary Cancers Symposium
Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer.
Authors
Bertrand Tombal
Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium
Bertrand Tombal , Michael Borre , Per Rathenborg , Patrick Werbrouck , Axel Heidenreich , Peter Iversen , Edwina S. Baskin-Bey , Frank Perabo , De Phung , Matthew Raymond Smith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01302041
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 18)
DOI
10.1200/jco.2013.31.6_suppl.18
Abstract #
18
Poster Bd #
B9
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR).
First Author: Andrew Leonard Laccetti
Poster
2023 ASCO Annual Meeting
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 2 randomized open-label study of oral darolutamide monotherapy vs. androgen deprivation therapy in men with hormone-naive prostate cancer (EORTC-GUCG 1532).
First Author: Bertrand F. Tombal
Poster
2022 ASCO Annual Meeting
A phase 1/2 multicenter investigator-initiated trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
First Author: David R Wise